OUR PIPELINE

MAKING
THE GREAT,
GREATER

We analyze the unmet needs of patients—continuously looking for ways to further improve therapies for those who need them. To help realize this goal, our teams have been hard at work to grow our portfolio of oncology, critical care, and orphan disease treatments through the development of biologics and small molecules.

THE TEAMS
AT WORK

 

Medical and Operations

Woodcliff Lake, NJ

Jupiter, FL

Biologics Formulation Development

Cambridge, MA

OUR PORTFOLIO AND PIPELINE CURRENTLY INCLUDES

RYANODEX® (dantrolene sodium) for Injectable Suspension

Learn more about RYANODEX and approved indications

Nerve-Agent Induced Brain Damage Investigational Indication

Prescribing Information

BELRAPZO® (bendamustine hydrochloride injection)

Learn more about BELRAPZO® and approved indications

Prescribing Information

PEMFEXY™ (pemetrexed injection)

Read about PEMFEXY’s tentative approval from the FDA

Fulvestrant

Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer, Who Have Gone Through Menopause and Have Not Been Previously Treated with Endocrine Therapy Investigational Indication, Clinical Trial Ongoing

HR-Positive Advanced Breast Cancer, Who Have Gone Through Menopause and Whose Disease Has Progressed After Endocrine Therapy Investigational Indication, Clinical Trial Ongoing

HR-Positive, HER2-Negative Advanced Breast Cancer or Breast Cancer That Has Spread to Other Parts Of The Body (Metastatic), in Combination With Palbociclib or Abemaciclib in Women Whose Disease Has Progressed After Endocrine Therapy  Investigational Indication, Clinical Trial Ongoing